SCHEMBL10049090

SCHEMBL10049090

CCn1nc(-c2ccc(C)cc2OC)cc1CO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ SUV39H2 Q9H5I1 1/20 0.36
▸ HSD17B10 Q99714 3/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CRHR1 P34998 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ POLB P06746 3/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ HPGD P15428 2/20 0.35
▸ BRD9 Q9H8M2 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CREBBP Q92793 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19936484 0.87 ALDH1A1 (0.37) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL10049095 0.86 HSP90AA1 (0.43) ALDH1A1KDM4ETSHRCRHR1TP53
SCHEMBL3436659 0.85 ACHE (0.40) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL3436657 0.85 ALDH1A1 (0.45) ALDH1A1KDM4EMAPTHSD17B10TP53
SCHEMBL10049093 0.83 CRHR1 (0.38) ALDH1A1KMT2AMEN1MAPTCRHR1
SCHEMBL3435083 0.80 KMT2A (0.47) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL10049017 0.77 CA1 (0.41) ACHESUV39H2CRHR1POLBTDP1
SCHEMBL19936650 0.75 KMT2A (0.36) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL19936567 0.73 HSP90AA1 (0.43) ALDH1A1KDM4ECRHR1TP53
SCHEMBL3436655 0.70 KCNH2 (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 — — EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 — — US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 — — US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 — — EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 — — US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 — — US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI ALDH1A1 1594/4885KDM4E 1069/4885KMT2A 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback